Table 1.
Patient characteristics.
| Variables | COVID-n = 117 (%) | Pre-COVID-n = 190 (%) | P-value |
|---|---|---|---|
| Mean age (SD) | 66.3 (10.8) | 65.1 (11.3) | 0.18 |
| Gender | 0.11 | ||
| Males | 100 (85.5) | 147 (77.4) | |
| Females | 17 (14.5) | 43 (22.6) | |
| Race | 0.06 | ||
| White | 91 (77.8) | 169 (88.9) | |
| Black | 11 (9.4) | 9 (4.7) | |
| Asian | 6 (5.1) | 6 (3.2) | |
| Other | 9 (7.7) | 6 (3.2) | |
| Histopathology | 0.49 | ||
| Adenocarcinoma | 84 (71.8) | 146 (76.8) | |
| Squamous cell | 29 (24.8) | 36 (18.9) | |
| Carcinoma unspecified | 4 (3.4) | 8 (4.2) | |
| Location of tumor | 0.52 | ||
| Upper-third | 8 (6.8) | 12 (5.9) | |
| Middle-third | 13 (11.0) | 34 (16.6) | |
| Lower-third | 58 (49.2) | 89 (43.4) | |
| GE-Junction | 39 (33.1) | 70 (34.1) | |
| BMI (median-IQR) | 27.1 (24.5-29.8) | 27.1 (23.2-31.3) | 0.92 |
| Weight loss-lbs. (median-IQR) | 11 (0-30) | 8 (0-20) | 0.14 |
| Comorbidities | |||
| Hypertension | 84 (71.8) | 133 (70.0) | 0.79 |
| Barrett's | 26 (22.2) | 63 (33.2) | 0.05 |
| Afib | 26 (22.2) | 55 (28.9) | 0.23 |
| Other Cancer | 18 (15.4) | 37 (19.5) | 0.44 |
| Diabetes | 33 (28.2) | 44 (23.2) | 0.34 |
| CHF | 4 (3.4) | 15 (7.9) | 0.14 |
| CAD | 24 (20.5) | 38 (20.0) | 1.0 |
| COPD | 12 (10.3) | 20 (10.5) | 1.0 |
| Smoking History | 68 (58.1) | 127 (66.8) | 0.14 |
| CKD | 12 (10.3) | 30 (15.8) | 0.23 |
| Liver disease | 6 (5.1) | 17 (8.9) | 0.26 |
| AJCC staging 8th ed | 0.34 | ||
| Stage 0 | 1 (0.9) | 1 (0.5) | |
| Stage 1 | 10 (8.5) | 28 (14.7) | |
| Stage 2 | 12 (10.3) | 28 (14.7) | |
| Stage 3 | 46 (39.3) | 61 (32.1) | |
| Stage 4 | 45 (38.5) | 70 (36.8) | |
| Unknown | 3 (2.6) | 2 (1) | |
| Visit type leading to diagnosis | 0.14 | ||
| Emergency Department | 35 (35.5) | 36 (26.7) | |
| Elective visit | 61 (63.5) | 99 (73.3) | |
| Covid test result | |||
| Positive | 3 (3.3) | ||
| Negative | 88 (96.7) | N/A |